FMOD and carcinoma: Treatment of experimental carcinoma with an inhibitor of PDGF receptors [35], with prostaglandin E1[19] or growth of carcinoma in fibromodulin-deficient mice [25] generate tumors that have an increased ECV and reduced IFP.